Covered recipient · General Payments record
EUGENE BLANCHARD CONE
Allopathic & Osteopathic Physicians Urology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$44,715.63
83 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Long term medical supply or device loan | $15,300.00 | 1 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $12,810.00 | 3 |
| Consulting Fee | $10,295.50 | 5 |
| Food and Beverage | $3,680.56 | 68 |
| Travel and Lodging | $2,629.57 | 6 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Central Indiana URS Consumables, LLC | $15,300.00 | 1 |
| Merck Sharp & Dohme LLC | $15,184.60 | 11 |
| Bayer Healthcare Pharmaceuticals Inc. | $3,921.99 | 5 |
| Janssen Scientific Affairs, LLC | $3,762.73 | 8 |
| PFIZER INC. | $2,798.61 | 5 |
| Janssen Biotech, Inc. | $1,879.42 | 13 |
| Dendreon Pharmaceuticals LLC | $578.73 | 11 |
| Astellas Pharma US Inc | $187.05 | 4 |
| IMMUNITYBIO, INC. | $176.71 | 1 |
| AstraZeneca Pharmaceuticals LP | $135.00 | 1 |
| Ferring Pharmaceuticals Inc. | $100.07 | 2 |
| Tempus AI, Inc | $92.41 | 1 |
| ACCORD HEALTHCARE, INC. | $89.68 | 1 |
| Novartis Pharmaceuticals Corporation | $83.87 | 2 |
| PROCEPT BioRobotics Corporation | $82.56 | 2 |
| Agiliti Surgical, Inc. | $79.40 | 2 |
| UROGEN PHARMA, INC. | $59.82 | 3 |
| PROGENICS PHARMACEUTICALS, INC. | $48.91 | 2 |
| Edap Technomed Inc | $45.00 | 3 |
| VERTEX PHARMACEUTICALS INCORPORATED | $25.92 | 1 |
| Tolmar, Inc. | $24.74 | 1 |
| Telix Pharmaceuticals | $19.97 | 1 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $19.33 | 1 |
| ABBVIE INC. | $19.11 | 1 |
Page 2 of 2; records 51–83 of 83 matching records. This page contains 33 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
EUGENE BLANCHARD CONE
NPI 1083955538 · CMS profile ID 6368399
Allopathic & Osteopathic Physicians / Urology
GREENWOOD, IN
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–83 of 83 matching records. This page contains 33 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1083955538?year=2024&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- EUGENE BLANCHARD CONE, NPI 1083955538, CMS profile ID 6368399. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–83 of 83 matching records. This page contains 33 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1083955538?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). EUGENE BLANCHARD CONE, NPI 1083955538, CMS profile ID 6368399. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–83 of 83 matching records. This page contains 33 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1083955538?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- EUGENE BLANCHARD CONE, NPI 1083955538, CMS profile ID 6368399, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–83 of 83 matching records. This page contains 33 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1083955538?year=2024&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
83 matching records · $44,715.63 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–83 of 83.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Astellas Pharma US Inc | $12.57 | 07/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139298726 | CMS |
| Merck Sharp & Dohme LLC | $18.53 | 06/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141726041 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $19.33 | 06/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152148770 | CMS |
| Janssen Biotech, Inc. | $125.68 | 05/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078619866 | CMS |
| Janssen Biotech, Inc. | $32.25 | 05/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078620277 | CMS |
| IMMUNITYBIO, INC. | $176.71 | 05/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1125508362 | CMS |
| ABBVIE INC. | $19.11 | 05/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103495624 | CMS |
| Astellas Pharma US Inc | $130.77 | 05/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139371433 | CMS |
| Ferring Pharmaceuticals Inc. | $51.86 | 05/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137470698 | CMS |
| Janssen Biotech, Inc. | $147.47 | 05/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078620241 | CMS |
| Janssen Biotech, Inc. | $17.31 | 05/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078620339 | CMS |
| Dendreon Pharmaceuticals LLC | $49.54 | 05/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1149314348 | CMS |
| Dendreon Pharmaceuticals LLC | $30.41 | 04/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1149314346 | CMS |
| Merck Sharp & Dohme LLC | $137.40 | 04/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141726043 | CMS |
| Dendreon Pharmaceuticals LLC | $25.46 | 03/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1149314344 | CMS |
| Dendreon Pharmaceuticals LLC | $123.11 | 03/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1149314342 | CMS |
| PROCEPT BioRobotics Corporation | $58.97 | 02/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1144030132 | CMS |
| PROGENICS PHARMACEUTICALS, INC. | $20.45 | 02/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1128514823 | CMS |
| Janssen Biotech, Inc. | $18.18 | 02/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078620004 | CMS |
| PFIZER INC. | $21.56 | 02/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131631634 | CMS |
| Agiliti Surgical, Inc. | $31.34 | 01/31/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1153264309 | CMS |
| Agiliti Surgical, Inc. | $48.06 | 01/31/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1153264397 | CMS |
| UROGEN PHARMA, INC. | $20.45 | 01/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137922717 | CMS |
| Dendreon Pharmaceuticals LLC | $27.38 | 01/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1149314340 | CMS |
| Ferring Pharmaceuticals Inc. | $48.21 | 01/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137470692 | CMS |
| Janssen Scientific Affairs, LLC | $41.36 | 01/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078850317 | CMS |
| ACCORD HEALTHCARE, INC. | $89.68 | 01/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1120076472 | CMS |
| Dendreon Pharmaceuticals LLC | $73.88 | 01/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1149314338 | CMS |
| Janssen Biotech, Inc. | $101.68 | 01/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078619935 | CMS |
| Dendreon Pharmaceuticals LLC | $157.58 | 01/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1149314336 | CMS |
| Astellas Pharma US Inc | $15.57 | 01/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139308082 | CMS |
| Merck Sharp & Dohme LLC | $100.00 | 01/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141726045 | CMS |
| Telix Pharmaceuticals | $19.97 | 01/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1081982278 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2022, 2023, 2024, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $765,866.83 | 95 |
| PY2024 | Principal investigator | $1,040,194.20 | 98 |
| PY2023 | Principal investigator | $169,181.80 | 28 |
| PY2022 | Principal investigator | $17,121.00 | 2 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
95 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Janssen Research & Development, LLC | $9,519.00 | 12/26/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175356660 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $1,962.00 | 12/22/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA LLC | RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) | No dispute reported | 06/30/2026 | 1176657724 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,570.00 | 12/16/2025 | Non-covered Recipient Entity Uro Of Indiana Llc Distr | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175216553 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,900.00 | 12/15/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA LLC | Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions | No dispute reported | 06/30/2026 | 1175357075 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,988.00 | 12/15/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA LLC | Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions | No dispute reported | 06/30/2026 | 1175357161 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,000.00 | 12/15/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA LLC | Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions | No dispute reported | 06/30/2026 | 1175357252 |
| Principal investigator 1 | Janssen Research & Development, LLC | $275.00 | 12/09/2025 | Non-covered Recipient Entity Uro Of Indiana Admin Ofc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175216583 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,077.84 | 12/09/2025 | Non-covered Recipient Entity Uro Of Indiana Llc Distr | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175216648 |
| Principal investigator 1 | Janssen Research & Development, LLC | $316.00 | 12/09/2025 | Non-covered Recipient Entity Uro Of Indiana Llc Distr | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175216679 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,446.00 | 11/27/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175356605 |
| Principal investigator 1 | Janssen Research & Development, LLC | $32,575.00 | 11/27/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175356652 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,500.00 | 11/27/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175356692 |
| Principal investigator 1 | Janssen Research & Development, LLC | $550.00 | 11/27/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175356718 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,322.00 | 11/27/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175356897 |
| Principal investigator 1 | Janssen Research & Development, LLC | $32,892.00 | 11/27/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175356954 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,714.00 | 11/24/2025 | Non-covered Recipient Entity Uro Of Indiana Admin Ofc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175216640 |
| Principal investigator 1 | Janssen Research & Development, LLC | $275.00 | 11/24/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA LLC | Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions | No dispute reported | 06/30/2026 | 1175357211 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,988.00 | 11/24/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA LLC | Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions | No dispute reported | 06/30/2026 | 1175357229 |
| Principal investigator 1 | PROGENICS PHARMACEUTICALS, INC. | $4,000.00 | 11/24/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA, LLC | PYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR | No dispute reported | 06/30/2026 | 1245230376 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,200.00 | 11/21/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175356554 |
| Principal investigator 1 | Janssen Research & Development, LLC | $550.00 | 11/21/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175356977 |
| Principal investigator 1 | Janssen Research & Development, LLC | $275.00 | 11/13/2025 | Non-covered Recipient Entity Uro Of Indiana Llc Distr | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175216516 |
| Principal investigator 1 | Janssen Research & Development, LLC | $225.00 | 11/12/2025 | Non-covered Recipient Entity Uro Of Indiana Admin Ofc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175216530 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,944.00 | 11/12/2025 | Non-covered Recipient Entity Uro Of Indiana Admin Ofc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175216730 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,570.00 | 11/07/2025 | Non-covered Recipient Entity Uro Of Indiana Llc Distr | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175216545 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,173.00 | 11/07/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175356811 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200.00 | 10/30/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA LLC | Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions | No dispute reported | 06/30/2026 | 1175357186 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,000.00 | 10/27/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA LLC | Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions | No dispute reported | 06/30/2026 | 1175357177 |
| Principal investigator 1 | PROGENICS PHARMACEUTICALS, INC. | $2,865.00 | 10/21/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA, LLC | PYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR | No dispute reported | 06/30/2026 | 1245230340 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,077.84 | 10/16/2025 | Non-covered Recipient Entity Uro Of Indiana Llc Distr | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175216591 |
| Principal investigator 1 | Janssen Research & Development, LLC | $316.00 | 10/15/2025 | Non-covered Recipient Entity Uro Of Indiana Llc Distr | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175216615 |
| Principal investigator 1 | Janssen Research & Development, LLC | $225.00 | 10/14/2025 | Non-covered Recipient Entity Uro Of Indiana Admin Ofc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175216538 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,944.00 | 10/14/2025 | Non-covered Recipient Entity Uro Of Indiana Admin Ofc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175216705 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,500.00 | 10/14/2025 | Non-covered Recipient Entity Uro Of Indiana Admin Ofc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175216737 |
| Principal investigator 1 | Janssen Research & Development, LLC | $36,000.00 | 10/09/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA LLC | Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions | No dispute reported | 06/30/2026 | 1175357007 |
| Principal investigator 1 | Janssen Research & Development, LLC | $25,384.00 | 10/06/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175356668 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,088.00 | 10/02/2025 | Non-covered Recipient Entity Uro Of Indiana Admin Ofc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175216603 |
| Principal investigator 1 | PROGENICS PHARMACEUTICALS, INC. | $1,450.00 | 09/29/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA, LLC | PYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR | No dispute reported | 06/30/2026 | 1245230322 |
| Principal investigator 1 | PROGENICS PHARMACEUTICALS, INC. | $3,000.00 | 09/29/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA, LLC | PYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR | No dispute reported | 06/30/2026 | 1245230328 |
| Principal investigator 1 | PROGENICS PHARMACEUTICALS, INC. | $15,000.00 | 09/29/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA, LLC | PYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR | No dispute reported | 06/30/2026 | 1245230332 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,183.00 | 09/22/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175356748 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,223.00 | 09/22/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175356993 |
| Principal investigator 1 | Janssen Research & Development, LLC | $474.00 | 09/17/2025 | Non-covered Recipient Entity Uro Of Indiana Admin Ofc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175216508 |
| Principal investigator 1 | Janssen Research & Development, LLC | $142.00 | 09/17/2025 | Non-covered Recipient Entity Uro Of Indiana Admin Ofc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175216561 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,393.84 | 09/17/2025 | Non-covered Recipient Entity Uro Of Indiana Llc Distr | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175216721 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,444.00 | 08/28/2025 | Non-covered Recipient Entity Uro Of Indiana Admin Ofc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175216596 |
| Principal investigator 1 | Janssen Research & Development, LLC | $273.00 | 08/18/2025 | Non-covered Recipient Entity Uro Of Indiana Llc Distr | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175216568 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,976.00 | 08/14/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA LLC | Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions | No dispute reported | 06/30/2026 | 1175357131 |
| Principal investigator 1 | Janssen Research & Development, LLC | $138.00 | 08/04/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA | A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC | No dispute reported | 06/30/2026 | 1175356598 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,900.00 | 07/30/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA LLC | Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions | No dispute reported | 06/30/2026 | 1175357242 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,173.00 | 07/28/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175356685 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 07/17/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175356583 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,446.00 | 07/17/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175356873 |
| Principal investigator 1 | Janssen Research & Development, LLC | $250.00 | 07/17/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175356965 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,570.00 | 07/14/2025 | Non-covered Recipient Entity Uro Of Indiana Llc Distr | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175216696 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,692.00 | 07/07/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175356819 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,800.00 | 06/23/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA LLC | Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions | No dispute reported | 06/30/2026 | 1175357031 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,954.00 | 06/13/2025 | Non-covered Recipient Entity Uro Of Indiana Admin Ofc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175216160 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,173.00 | 06/09/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175356562 |
| Principal investigator 1 | Janssen Research & Development, LLC | $17,768.00 | 06/09/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175356763 |
| Principal investigator 1 | Janssen Research & Development, LLC | $17,768.00 | 06/09/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175356905 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,338.00 | 06/02/2025 | Non-covered Recipient Entity Uro Of Indiana Admin Ofc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175216576 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,600.00 | 05/23/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA LLC | Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions | No dispute reported | 06/30/2026 | 1175357203 |
| Principal investigator 1 | Janssen Research & Development, LLC | $173.00 | 05/22/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175356570 |
| Principal investigator 1 | Janssen Research & Development, LLC | $26,652.00 | 05/22/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175356757 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,644.00 | 05/22/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175356854 |
| Principal investigator 1 | Janssen Research & Development, LLC | $44,420.00 | 05/19/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175356888 |
| Principal investigator 1 | Janssen Research & Development, LLC | $275.00 | 05/09/2025 | Non-covered Recipient Entity Uro Of Indiana Admin Ofc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175216169 |
| Principal investigator 1 | Janssen Research & Development, LLC | $474.00 | 05/09/2025 | Non-covered Recipient Entity Uro Of Indiana Admin Ofc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175216210 |
| Principal investigator 1 | Janssen Research & Development, LLC | $275.00 | 05/09/2025 | Non-covered Recipient Entity Uro Of Indiana Llc Distr | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175216663 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,393.84 | 05/09/2025 | Non-covered Recipient Entity Uro Of Indiana Llc Distr | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175216670 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,192.00 | 04/28/2025 | Non-covered Recipient Entity Uro Of Indiana Admin Ofc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175216197 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,584.00 | 04/28/2025 | Non-covered Recipient Entity Uro Of Indiana Llc Distr | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175216623 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,692.00 | 04/28/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175356913 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,767.00 | 04/03/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175356879 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,818.00 | 03/17/2025 | Non-covered Recipient Entity Uro Of Indiana Admin Ofc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175216174 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,400.00 | 03/07/2025 | Non-covered Recipient Entity Uro Of Indiana Admin Ofc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175216182 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,000.00 | 03/07/2025 | Non-covered Recipient Entity Uro Of Indiana Admin Ofc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175216190 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,346.00 | 03/07/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175356970 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,722.00 | 02/21/2025 | Non-covered Recipient Entity Uro Of Indiana Admin Ofc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175216147 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,500.00 | 02/21/2025 | Non-covered Recipient Entity Uro Of Indiana Llc Distr | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175216631 |
| Principal investigator 1 | Janssen Research & Development, LLC | $450.00 | 02/21/2025 | Non-covered Recipient Entity Uro Of Indiana Llc Distr | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175216655 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,800.00 | 02/21/2025 | Non-covered Recipient Entity Uro Of Indiana Llc Distr | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175216689 |
| Principal investigator 1 | Janssen Research & Development, LLC | $275.00 | 02/17/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175356614 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,619.00 | 02/17/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175356635 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,446.00 | 02/17/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175356786 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,884.00 | 02/17/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175356803 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,555.00 | 02/13/2025 | Non-covered Recipient Entity Uro Of Indiana Llc Distr | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175216525 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,461.00 | 02/10/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175356643 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,537.00 | 02/03/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA | A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC | No dispute reported | 06/30/2026 | 1175356621 |
| Principal investigator 1 | Janssen Research & Development, LLC | $275.00 | 01/30/2025 | Non-covered Recipient Entity Uro Of Indiana Llc Distr | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175216610 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $129,443.87 | 01/29/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA | a phase 3b,open label,single arm,multi center,US study of bacillus calmette guerin bcg administered in combination with durvalumab in adult bcg naive,high risk non muscle invasive bladder cancer participants patapsco | No dispute reported | 06/30/2026 | 1185545057 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $606.60 | 01/29/2025 | Non-covered Recipient Entity UROLOGY OF INDIANA LLC | RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) | No dispute reported | 06/30/2026 | 1176624963 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,096.00 | 01/28/2025 | Non-covered Recipient Entity Uro Of Indiana Admin Ofc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175216153 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,555.00 | 01/14/2025 | Non-covered Recipient Entity Uro Of Indiana Llc Distr | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175216712 |
Ownership and Investment Interests
One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together
| Program year | Measure | Amount | Records |
|---|---|---|---|
| PY2025 | Amount invested | $10,480.00 | 1 |
| PY2025 | Value of interest | $15,600.00 | 1 |
| PY2024 | Amount invested | $10,480.00 | 1 |
| PY2024 | Value of interest | $10,480.00 | 1 |
Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.
Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.
Ownership and Investment Interests records
Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them
2 records · PY2024–2025
| Program year | Company | Amount invested | Value of interest | Terms of interest | Interest held by | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| PY2025 | Central Indiana URS Consumables, LLC | $10,480.00 | $15,600.00 | LLC Membership Interest | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1188127773 |
| PY2024 | Central Indiana URS Consumables, LLC | $10,480.00 | $10,480.00 | LLC Membership Interest | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1123484358 |